Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
QurAlis, a start-up based in Cambridge, Massachusetts, has raised $42 million in series A financing to develop small-molecule and antisense oligonucleotide drugs for two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The company plans to discover drugs that individually target one of nearly 30 genes implicated in ALS. Many of these genes are also implicated in FTD. Its lead programs are focused on drugging a potassium channel and an enzyme that regulates autophagy.
This article has been sent to the following recipient: